Overview
BiotechPhase 3MDMALSDOtherHiring
Formerly MindMed, rebranded to Definium Therapeutics in January 2026. Developing DT120 (LSD) for generalized anxiety disorder and major depressive disorder. Three Phase 3 readouts expected in 2026.
Visit WebsiteNew York, NY
7
Clinical Trials
2019
Founded
80
Employees
17
Open Roles
Open Positions(17)
Research Areas
Clinical Pipeline(7)
Recruiting·Phase 2·MDMA
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))Autism Spectrum Disorder
Active, Not Recruiting·Phase 3·LSD
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
PlaceboGeneralized Anxiety Disorder
Recruiting·Phase 3·Other
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
PlaceboMajor Depressive Disorder
Completed·Phase 2·LSD
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
MM120Anxiety Generalized
Active, Not Recruiting·Phase 3·LSD
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
PlaceboGeneralized Anxiety Disorder
Completed·Phase 2·LSD
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
MM120ADHD
Active, Not Recruiting·Phase 3·LSD
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
PlaceboMajor Depressive Disorder